US Stock Market Move | Wave Life Sciences (WVE.US) continues to rise nearly 10% in pre-market trading, following a 147% surge yesterday.

After surging 147% on Monday, Wave Life Sciences (WVE.US) continued to rise nearly 10% in pre-market trading on Tuesday, reaching $20.28. In terms of news, on December 8th, Wave Life Sciences announced the interim data from the Phase I INLIGHT trial of its obesity candidate drug WVE-007. The data came from 32 subjects who received a single 240mg subcutaneous injection, showing a 9.4% reduction in visceral fat, a 4.5% decrease in total body fat, and a 3.2% increase in lean body mass after 12 weeks. The Phase I INLIGHT trial of WVE-007 demonstrated that after a single 240mg subcutaneous injection for 12 weeks, subjects with a BMI of 28-35 kg/m experienced a 9.4% reduction in visceral fat (p=0.02), a 4.5% decrease in total body fat, and a 3.2% increase in lean body mass (approximately 4 pounds). Overall body weight only decreased by 0.9% due to muscle growth offsetting the reduction. Serum levels of Activin E reached a maximum inhibition of 78% at 43 days and the efficacy was sustained for over 85 days, supporting the potential for dosing once or twice a year.